Choreo LLC Reduces Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Choreo LLC lowered its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 12.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,033 shares of the company’s stock after selling 2,952 shares during the quarter. Choreo LLC’s holdings in Takeda Pharmaceutical were worth $264,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of TAK. Versant Capital Management Inc purchased a new position in shares of Takeda Pharmaceutical during the 4th quarter worth approximately $26,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Takeda Pharmaceutical during the third quarter valued at approximately $40,000. BNP Paribas Financial Markets grew its stake in Takeda Pharmaceutical by 416.0% in the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after purchasing an additional 2,596 shares during the period. Smithfield Trust Co raised its holdings in Takeda Pharmaceutical by 76.9% in the third quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after purchasing an additional 1,490 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new position in Takeda Pharmaceutical during the third quarter valued at $52,000. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Stock Down 0.6 %

NYSE:TAK opened at $13.54 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The firm’s 50-day moving average price is $13.27 and its 200-day moving average price is $13.88. The company has a market capitalization of $43.07 billion, a PE ratio of 33.84, a P/E/G ratio of 0.24 and a beta of 0.51. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, equities analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.